#1 Clinical Trials Search in Europe

Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate is a chemotherapy drug being studied in various clinical trials for treating different types of cancer. This article explores how this medication is being used in combination with other therapies to potentially improve outcomes for patients with conditions like lymphoma, breast cancer, and other advanced cancers. We’ll look at some key trials examining its effectiveness, safety, and optimal dosing strategies.

Table of Contents

What is Cyclophosphamide?

Cyclophosphamide is a powerful medication used in the treatment of various cancers and autoimmune disorders. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing[1]. Cyclophosphamide is also known by other names, including Cytoxan and Endoxan[2][3].

Conditions Treated with Cyclophosphamide

Cyclophosphamide is used to treat a variety of conditions, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells[4][3]
  • Breast Cancer: Particularly in early-stage and metastatic forms[5][6]
  • Colorectal Cancer: Especially in metastatic cases[2]
  • Non-Small Cell Lung Cancer[7]
  • Sarcomas: Including synovial sarcoma and soft tissue sarcomas[7]
  • Melanoma: Particularly stage IV[7]
  • Bladder Urothelial Carcinoma[7]
  • Neuroblastoma: A type of cancer that develops from immature nerve cells[7]

How Cyclophosphamide Works

Cyclophosphamide is a type of chemotherapy drug that works by damaging the DNA of rapidly dividing cells, such as cancer cells. This damage prevents the cells from reproducing and ultimately leads to their death. While it primarily targets cancer cells, it can also affect other fast-growing cells in the body, which is why it may cause side effects[1].

How Cyclophosphamide is Administered

Cyclophosphamide can be administered in several ways, depending on the specific treatment plan:

  • Oral tablets: Taken daily at a low dose in some regimens[2]
  • Intravenous (IV) infusion: Given through a vein, often as part of a combination therapy[1]
  • Different dosing schedules: Can be given in high doses less frequently or in lower doses more frequently (known as metronomic dosing)[6]

The specific dosage and schedule will depend on the condition being treated, the patient’s overall health, and other factors determined by the healthcare team.

Combination Therapies

Cyclophosphamide is often used in combination with other medications to enhance its effectiveness. Some common combination therapies include:

  • FEC regimen: Fluorouracil, Epirubicin, and Cyclophosphamide, used in breast cancer treatment[5]
  • FOLFOXIRI plus Bevacizumab: A combination used in colorectal cancer treatment that includes cyclophosphamide[1]
  • Cyclophosphamide with Bortezomib (Velcade) and G-CSF: Used in multiple myeloma treatment[3]
  • Metronomic chemotherapy: Low-dose cyclophosphamide combined with other drugs like capecitabine, methotrexate, and celecoxib[2]

Potential Side Effects

Like all medications, cyclophosphamide can cause side effects. Some potential side effects include:

  • Hematologic toxicities: Such as low white blood cell count (neutropenia) or low platelet count (thrombocytopenia)[4]
  • Nausea and vomiting[8]
  • Hair loss (alopecia)[8]
  • Fatigue
  • Increased risk of infections due to lowered immune function

Your healthcare team will monitor you closely for these side effects and may adjust your treatment as needed.

Ongoing Research and Clinical Trials

Researchers continue to study cyclophosphamide to find new ways to use it effectively and safely. Some areas of ongoing research include:

  • Metronomic chemotherapy: Using low, frequent doses of cyclophosphamide to potentially reduce side effects and improve efficacy[2]
  • Combination therapies: Testing cyclophosphamide with newer drugs or in different combinations to improve treatment outcomes[7]
  • Stem cell mobilization: Using cyclophosphamide to help collect stem cells for transplantation in multiple myeloma patients[3]
  • Neoadjuvant therapy: Using cyclophosphamide before surgery in breast cancer patients to potentially improve outcomes[6]

These ongoing studies aim to optimize the use of cyclophosphamide and improve patient outcomes across various cancer types.

Trial Focus Cancer Type Combination Therapy Key Outcomes Measured
CAR-T cell therapy Large B-cell Lymphoma Fludarabine, Axicabtagene Ciloleucel Safety, efficacy, cytokine release syndrome
Immunotherapy combination Metastatic Renal Cell Carcinoma Pembrolizumab Objective response rate, progression-free survival
Low-dose metronomic Metastatic Breast Cancer Veliparib Recommended phase II dose, clinical benefit
Older patient focus Multiple Myeloma MUC1-activated T-cells Safety, feasibility, immune response
Dose reduction study Early-stage Breast Cancer Docetaxel Relative dose intensity, treatment tolerability

FAQ

  • What types of cancer is Cyclophosphamide Monohydrate being studied for? Cyclophosphamide Monohydrate is being studied in clinical trials for various cancers including lymphoma, breast cancer, renal cell carcinoma, gastric cancer, and prostate cancer. It's often used in combination with other treatments like immunotherapies or targeted therapies.
  • How is Cyclophosphamide Monohydrate typically administered? Cyclophosphamide Monohydrate is usually given intravenously (through an IV) or orally as a pill. The dosing and schedule can vary depending on the specific trial and treatment regimen. Some trials are exploring lower dose 'metronomic' dosing given more frequently.
  • What are some potential side effects of Cyclophosphamide Monohydrate? Common side effects can include nausea, hair loss, fatigue, and increased risk of infections. More serious side effects may include bladder problems, fertility issues, and secondary cancers. Side effects are closely monitored in clinical trials.
  • Why is Cyclophosphamide Monohydrate often combined with other drugs in trials? Combining Cyclophosphamide Monohydrate with other treatments may improve effectiveness against cancer. For example, it's being studied with immunotherapies to potentially enhance the immune response against tumors.
  • Are there any trials looking at Cyclophosphamide Monohydrate for older or more vulnerable patients? Yes, some trials are exploring lower doses or alternative schedules of Cyclophosphamide Monohydrate for older or more vulnerable patients to reduce side effects while maintaining effectiveness. This includes studies in breast cancer and multiple myeloma.

Ongoing Clinical Trials on Cyclophosphamide Monohydrate

  • Study of Larotrectinib and Drug Combination for Children with Newly Diagnosed High-Grade Glioma with NTRK Fusion

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia Finland France Germany Greece +6

  • Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +13

  • Study on UCART20x22 for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on the Benefits of Autologous Stem Cell Transplantation for Patients with Peripheral T-cell Lymphoma Using Etoposide and Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study of TranspoCART19 Infusion for Patients with Relapsed or Refractory B-cell Lymphoma Using Genetically Modified T Lymphocytes

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

  • A study of Cesnicabtagene autoleucel compared to a drug combination for patients with relapsed or refractory multiple myeloma

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    The Netherlands

  • A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Germany Italy Spain

  • Study of KYV-101, Fludarabine Phosphate, and Cyclophosphamide Monohydrate for Patients with Treatment-Resistant ANCA Vasculitis

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Germany

  • Study on CCTx-001, Cyclophosphamide Monohydrate, and Fludarabine Phosphate for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    France Germany Spain Sweden

Glossary

  • Cyclophosphamide Monohydrate: A chemotherapy drug used to treat various types of cancer. It works by damaging the DNA of cancer cells, preventing them from dividing and growing.
  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Refractory: A disease that does not respond to treatment.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • CAR-T therapy: A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.
  • Cytokine release syndrome: A condition that may occur after some types of immunotherapy, causing symptoms like fever, nausea, and headache.
  • Metronomic dosing: A method of giving low doses of chemotherapy drugs on a frequent or continuous schedule.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival: The length of time from the start of treatment that patients are still alive.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. https://clinicaltrials.gov/study/NCT02271464
  2. https://clinicaltrials.gov/study/NCT02280694
  3. https://clinicaltrials.gov/study/NCT01146834
  4. https://clinicaltrials.gov/study/NCT01346787
  5. https://clinicaltrials.gov/study/NCT00055679
  6. https://clinicaltrials.gov/study/NCT00542191
  7. https://clinicaltrials.gov/study/NCT05296564
  8. https://clinicaltrials.gov/study/NCT02225652